Characterization of PRAME immunohistochemistry reveals lower expression in pediatric melanoma compared to adult melanoma.
PRAME
age dependency
dermatopathology
immunohistochemistry
pediatric melanoma
prognostic factor
Journal
Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927
Informations de publication
Date de publication:
20 Mar 2024
20 Mar 2024
Historique:
revised:
04
03
2024
received:
15
01
2024
accepted:
12
03
2024
medline:
21
3
2024
pubmed:
21
3
2024
entrez:
21
3
2024
Statut:
aheadofprint
Résumé
Pediatric melanomas are rare tumors that have clinical and histological differences from adult melanomas. In adult melanoma, the immunohistochemical marker PRAME is increasingly employed as a diagnostic adjunct. PRAME is also under investigation as a target structure for next-generation immunotherapies including T-cell engagers. Little is known about the characteristics of PRAME expression in pediatric melanoma. In this retrospective study, samples from 25 pediatric melanomas were compared with control groups of melanomas in young adults (18-30 years; n = 32), adult melanoma (>30 years, n = 30), and benign melanocytic nevi in children (0-18 years; n = 30) with regard to the immunohistochemical expression of PRAME (diffuse PRAME expression >75%/absolute expression). Pediatric melanomas show lower diffuse PRAME expression (4%) and lower absolute PRAME expression (25%) compared to young adult melanomas (15.6%/46.8%) and adult melanomas (50%/70%). A significant age-dependent expression could be observed. An analysis of event-free survival shows no prognostic role for PRAME in pediatric melanoma and young adult melanoma, but a significant association with diffuse PRAME expression in adulthood. The age dependency of PRAME expression poses a potential pitfall in the diagnostic application of melanocytic tumors in young patients and may limit therapeutic options within this age group. The immunohistochemical expression of the tumor-associated antigen PRAME is an increasingly important diagnostic marker for melanocytic tumors and is gaining attention as a possible immunotherapeutic target in melanoma. As the available data primarily stem from adult melanoma, and given the clinical and histological distinctions in pediatric melanomas, our understanding of PRAME expression in this specific patient group remains limited. The age-dependent low PRAME expression shown here constrains the use of this marker in pediatric melanoma and may also limit the use of immunotherapeutic strategies against PRAME in young patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.
Références
Ademuyiwa, F. O., Bshara, W., Attwood, K., Morrison, C., Edge, S. B., Karpf, A. R., James, S. A., Ambrosone, C. B., O'Connor, T. L., Levine, E. G., Miliotto, A., Ritter, E., Ritter, G., Gnjatic, S., & Odunsi, K. (2012). NY‐ESO‐1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One, 7(6), e38783.
Bello, G. L., Pini, G. M., Giagnacovo, M., & Patriarca, C. (2023). PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases. Pathology, Research and Practice, 251, 154915.
Boutko, A., Hagstrom, M., Lampley, N., Roth, A., Olivares, S., Dhillon, S., Fumero‐Velázquez, M., Benton, S., Zhao, J., Zhang, B., Dittmann, D., Asadbeigi, S., Busam, K. J., & Gerami, P. (2023). PRAME immunohistochemical expression and TERT promoter mutational analysis as ancillary diagnostic tools for differentiating proliferative nodules from melanoma arising in congenital nevi. The American Journal of Dermatopathology, 45(7), 437–447.
Bunk, S., Hofmann, M., Unverdorben, F., Hutt, M., Pszolla, G., Schwöbel, F., Wagner, C., Yousef, S., Schuster, H., Missel, S., Schoor, O., Weinschenk, T., Singh‐Jasuja, H., Maurer, D., & Reinhardt, C. (2019). Effective targeting of PRAME‐positive tumors with bispecific T cell‐engaging receptor (TCER®) molecules. Blood, 134, 3368.
Cai, L., Paez‐Escamilla, M., Walter, S. D., Tarlan, B., Decatur, C. L., Perez, B. M., & Harbour, J. W. (2018). Gene expression profiling and PRAME status versus tumor‐node‐metastasis staging for prognostication in uveal melanoma. American Journal of Ophthalmology, 195, 154–160.
Chen, X., Wang, L., Yue, D., Liu, J., Huang, L., Yang, L., Cao, L., Qin, G., Li, A., Wang, D., Wang, M., Qi, Y., Zhang, B., van der Bruggen, P., & Zhang, Y. (2017). Correlation between the high expression levels of cancer‐germline genes with clinical characteristics in esophageal squamous cell carcinoma. Histology and Histopathology, 32(8), 793–803.
Church, A. J., Moustafa, D., Pinches, R. S., Hawryluk, E. B., & Schmidt, B. A. R. (2022). Genomic comparison of malignant melanoma and atypical Spitz tumor in the pediatric population. Pediatric Dermatology, 39(3), 409–419.
Ferrari, A., Brecht, I. B., Gatta, G., Schneider, D. T., Orbach, D., Cecchetto, G., Godzinski, J., Reguerre, Y., Bien, E., Stachowicz‐Stencel, T., Ost, M., Magni, C., Kearns, P., Vassal, G., Massimino, M., Biondi, A., Bisogno, G., & Trama, A. (2019). Defining and listing very rare cancers of paediatric age: Consensus of the joint action on rare cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. European Journal of Cancer, 110, 120–126.
Field, M. G., Decatur, C. L., Kurtenbach, S., Gezgin, G., van der Velden, P. A., Jager, M. J., Kozak, K. N., & Harbour, J. W. (2016). PRAME as an independent biomarker for metastasis in uveal melanoma. Clinical Cancer Research, 22(5), 1234–1242.
Gassenmaier, M., Hahn, M., Metzler, G., Bauer, J., Yazdi, A. S., Keim, U., Garbe, C., Wagner, N. B., & Forchhammer, S. (2021). Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non‐metastasizing thin melanomas. Cancers, 13(15), 3864.
Gezgin, G., Luk, S. J., Cao, J., Dogrusöz, M., van der Steen, D. M., Hagedoorn, R. S., Krijgsman, D., van der Velden, P. A., Field, M. G., Luyten, G. P. M., Szuhai, K., Harbour, J. W., Jordanova, E. S., Heemskerk, M. H. M., & Jager, M. J. (2017). PRAME as a potential target for immunotherapy in metastatic uveal melanoma. JAMA Ophthalmology, 135(6), 541–549.
Gill, P., Prieto, V. G., Austin, M. T., Giubellino, A., & Torres‐Cabala, C. A. (2021). Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi. Journal of Cutaneous Pathology, 48(11), 1410–1415.
Gradecki, S. E., Slingluff, C. L., Jr., & Gru, A. A. (2021). PRAME expression in 155 cases of metastatic melanoma. Journal of Cutaneous Pathology, 48(4), 479–485.
Gradecki, S. E., Valdes‐Rodriguez, R., Wick, M. R., & Gru, A. A. (2021). PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology, 78(7), 1000–1008.
Gutzmer, R., Rivoltini, L., Levchenko, E., Testori, A., Utikal, J., Ascierto, P. A., Demidov, L., Grob, J. J., Ridolfi, R., Schadendorf, D., Queirolo, P., Santoro, A., Loquai, C., Dreno, B., Hauschild, A., Schultz, E., Lesimple, T. P., Vanhoutte, N., Salaun, B., … Lehmann, F. F. (2016). Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: Results of a phase I dose escalation study. ESMO Open, 1(4), e000068.
Lezcano, C., Jungbluth, A. A., Nehal, K. S., Hollmann, T. J., & Busam, K. J. (2018). PRAME expression in melanocytic tumors. The American Journal of Surgical Pathology, 42(11), 1456–1465.
Merkel, E. A., Mohan, L. S., Shi, K., Panah, E., Zhang, B., & Gerami, P. (2019). Paediatric melanoma: clinical update, genetic basis, and advances in diagnosis. The Lancet Child & Adolescent Health, 3(9), 646–654.
O'Connor, M. K., Dai, H., & Fraga, G. R. (2022). PRAME immunohistochemistry for melanoma diagnosis: A STARD‐compliant diagnostic accuracy study. Journal of Cutaneous Pathology, 49(9), 780–786.
Pampena, R., Piccolo, V., Muscianese, M., Kyrgidis, A., Lai, M., Russo, T., Briatico, G., di Brizzi, E. V., Cascone, G., Pellerone, S., Longo, C., Moscarella, E., & Argenziano, G. (2023). Melanoma in children: A systematic review and individual patient meta‐analysis. Journal of the European Academy of Dermatology and Venereology, 37, 1758–1776.
Raghavan, S. S., Peternel, S., Mully, T. W., North, J. P., Pincus, L. B., LeBoit, P. E., McCalmont, T. H., Bastian, B. C., & Yeh, I. (2020). Spitz melanoma is a distinct subset of spitzoid melanoma. Modern Pathology, 33(6), 1122–1134.
Raghavan, S. S., Wang, J. Y., Kwok, S., Rieger, K. E., Novoa, R. A., & Brown, R. A. (2020). PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features. Journal of Cutaneous Pathology, 47(12), 1123–1131.
Sailer, N., Fetzer, I., Salvermoser, M., Braun, M., Brechtefeld, D., Krendl, C., Geiger, C., Mutze, K., Noessner, E., Schendel, D., Bürdek, M., Wilde, S., & Sommermeyer, D. (2022). T‐cells expressing a highly potent PRAME‐specific T‐cell receptor in combination with a chimeric PD1‐41BB co‐stimulatory receptor show a favorable preclinical safety profile and strong anti‐tumor reactivity. Cancers, 14(8), 1998.
Strouse, J. J., Fears, T. R., Tucker, M. A., & Wayne, A. S. (2005). Pediatric melanoma: Risk factor and survival analysis of the surveillance, epidemiology and end results database. Journal of Clinical Oncology, 23(21), 4735–4741.
Tio, D., Willemsen, M., Krebbers, G., Kasiem, F. R., Hoekzema, R., van Doorn, R., Bekkenk, M. W., & Luiten, R. M. (2020). Differential expression of cancer testis antigens on lentigo maligna and lentigo maligna melanoma. The American Journal of Dermatopathology, 42(8), 625–627.
Turner, N., Ko, C. J., McNiff, J. M., & Galan, A. (2023). Pitfalls of PRAME immunohistochemistry in a large series of melanocytic and nonmelanocytic lesions with literature review. The American Journal of Dermatopathology, 46, 21–30.
Umano, G. R., Errico, M. E., D'Onofrio, V., Delehaye, G., Trotta, L., Spinelli, C., Strambi, S., Franco, R., D'Abbronzo, G., Ronchi, A., & Papparella, A. (2021). The challenge of melanocytic lesions in pediatric patients: Clinical‐pathological findings and the diagnostic value of PRAME. Frontiers in Oncology, 11, 688410.